RxDoctor Payments Data

Amber Dvorak

Nurse Practitioner · West Des Moines, IANPI 1275073108

Payments from drug & device makers

$775in general payments, 2019–2025

Across 24 payments — averaging $32.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$217
  • Sanofi$142
  • Ferring Pharmaceuticals Inc.$137
  • Johnson & Johnson$95
  • Takeda Pharmaceuticals U.S.A., Inc.$59
  • Nestle Healthcare Nutrition Inc.$25
  • plus $99 from 5 others

What the payments were for

  • Food & beverage$75598%
  • Education$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$775 in reported general payments places this provider in the 80th percentile of 1,346 nurse practitioner providers in Iowa.

See all nurse practitioner providers in Iowa

Medicare billing

Part B allowed, 2024
$68,209
Medicare patients
385
Services billed
1,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide118$95,400
Dexlansoprazole DrDexlansoprazole59$13,732
Mesalamine18$5,670
Pantoprazole Sodium382$4,663
Colesevelam Hcl32$4,537
CholestyramineCholestyramine (With Sugar)71$3,867
NexiumEsomeprazole Magnesium12$3,770
Lubiprostone13$3,429
Colestipol Hcl49$3,226
Budesonide DrBudesonide20$2,614
Omeprazole231$1,766
Esomeprazole Magnesium79$1,504
Lactulose45$1,097
Rabeprazole Sodium21$999
Azathioprine12$958

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$217$95,400118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,346 nurse practitioner providers in Iowa.

Other nurse practitioner in West Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →